323990.KQ
Vaxcell-Bio Therapeutics Co., Ltd.
KOE · Healthcare · Biotechnology · KR
KRW 4,490.00
−10.56%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 6.5B | 7.1B | 1.9B | 13.7M | — |
| Cost of Revenue | 7.7B | 8.1B | 1.5B | 6.6M | 16.4M |
| Gross Profit | (1.2B) | (1.1B) | 364.8M | 7.1M | (16.4M) |
| Operating Expenses | |||||
| R&D Expense | 5.3B | 5.5B | 6.0B | 4.9B | 2.1B |
| SG&A Expense | 5.5B | 3.2B | 3.5B | 3.2B | 2.3B |
| General & Admin Expense | 1.7B | 1.5B | 1.5B | 821.4M | 508.2M |
| Selling & Marketing Expense | 1.5B | 1.8B | 2.0B | 2.4B | 1.8B |
| Other Expenses | 4.3B | 5.8B | 5.9B | 3.4B | 1.0B |
| Total Operating Expenses | 14.2B | 14.5B | 15.4B | 11.5B | 8.2B |
| Cost and Expenses | 23.3B | 22.6B | 16.9B | 11.5B | 8.2B |
| Operating Income (EBIT) | (16.8B) | (15.6B) | (15.0B) | (11.5B) | (8.2B) |
| Non-Operating | |||||
| Interest Income | 996.6M | 1.4B | 2.6B | 1.2B | 421.9M |
| Interest Expense | 197.9M | 224.6M | 225.1M | 43.7M | 16.7M |
| Net Interest Income | 798.8M | 1.2B | 2.4B | 1.1B | 405.2M |
| Other Non-Op Income/Expense | 1.9B | 2.3B | 4.4B | 1.2B | 1.4B |
| Non-Operating Income (excl Interest) | (294.0M) | — | (4.6B) | (1.3B) | (1.4B) |
| EBT (Pre-Tax Income) | (14.9B) | (13.3B) | (10.6B) | (10.3B) | (6.8B) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (14.9B) | (13.3B) | (10.6B) | (10.3B) | (6.8B) |
| Earnings from Cont. Ops | (14.9B) | (13.3B) | (10.6B) | (10.3B) | (6.8B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (14.9B) | (13.3B) | (10.6B) | (10.3B) | (6.8B) |
| Per Share | |||||
| Basic EPS | (₩643) | (₩577) | (₩463) | (₩524) | (₩338) |
| Diluted EPS | (₩643) | (₩577) | (₩463) | (₩524) | (₩338) |
| Revenue Per Share | ₩281 | ₩303 | ₩83 | ₩1 | ₩0 |
| Shares | |||||
| Basic Shares Outstanding | 23.2M | 23.3M | 22.9M | 19.6M | 20.2M |
| Diluted Shares Outstanding | 23.2M | 23.3M | 22.9M | 19.6M | 20.2M |
| Profitability Metrics | |||||
| EBITDA | (13.5B) | (13.4B) | (8.9B) | (9.8B) | (6.5B) |
| D&A | 2.4B | 2.2B | 1.5B | 399.7M | 311.3M |
| EBIT | (15.9B) | (15.6B) | (10.4B) | (10.2B) | (6.8B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026